DEVELOPMENT AND EVALUATION OF PATIENT-FRIENDLY DISPERSIBLE TABLETS FOR PEDIATRIC AND GERIATRIC DRUG DELIVERY
Main Article Content
Keywords
Dispersible tablets, Pediatric, Geriatric drug delivery.
Abstract
The production of a pharmaceutical that is suitable for use by humans should be the main focus of any endeavour that is geared toward the development of a drug delivery system (DDS). A tablet that can be easily dispersed in the mouth reduces the need for several formulations of the same medicine. The rapid dispersible drug delivery system was developed so that people who needed help taking their medicine may do it in a way that was reliable and consistent. Over the last several years, there has been a discernible increase in research efforts directed toward the development of drug delivery systems that have a pleasant flavour, are easy for patients to use, and are risk-free for both young people and older people. Due to the fact that their bioavailability is higher than that of standard oral dose forms, rapid dispersible and dissolving formulations are considered to be the best way of administration when it comes to dosing. The primary objective of the research being conducted in this field is to identify an original technique for the production of quick- dissolving tablets. Increasing the active ingredient's solubility, improving the drug's organoleptic qualities, and encouraging patients to take their medication are some of the suggestions that have been made here. These are just some of the ways that the bioavailability of the active ingredient can be increased in vivo. Due to the fact that this formulation was developed for people of all ages, including children and the elderly, it may be beneficial to use.
References
1. Salunke, S, Liu, F, Batchelor, H, Walsh, J, Turner, R, Ju, TR & Tuleu, C 2017, „European Paediatric Formulation Initiative (EuPFI)- Formulating Ideas for Better Medicines for Children‟, AAPS PharmSciTech, vol. 18, no. 2, pp. 257-262.
2. AAP (American Academy of Pediatrics), Committee on Drugs. Inactive ingredients in pharmaceutical products: update (subject review). Pediatrics, 1997; 99:268–78.
3. Aastha S, Srinivas N and Sravanthi M., “Formulation and In-Vitro Evaluation of Matrix Type Sustained Release Tablets of Paliperidone”, Innovations in Pharmaceuticals and Pharmacotherapy, 2013, 1 (3), 185-198.
4. Abdul H, Gopinath M, “Formulation and evaluation of Paliperidone Nanocrystals”, Bio Med Rx, 2013, 1 (5), 422-438.
5. Aboelwafa, A. A., & Fahmy, R. H. (2012). A pilot human pharmacokinetic study and influence of formulation factors on orodispersible tablet incorporating meloxicam solid dispersion using factorial design. Pharmaceutical development and technology, 17(1), 1-14.
6. Adolfsson Å˚ , Olsson H, Nyström C. Effect of particle size and compaction load on interparticulate bonding structure for some pharmaceutical materials studied by compaction and strength characterisation in butanol. Eur J Pharm Biopharm. 1997;44(3):243–51.
7. Afaque RMA, Saddamhusen JM, Gosavi JP. Review on artificial sweeteners used in formulation of sugar free syrups. Int J Adv Pharm, 2015; 4(2):2,4.
8. Aleksovski, A., Dreu, R., Gašperlin, M., & Planinšek, O. (2015). Mini-tablets: a contemporary system for oral drug delivery in targeted patient groups. Expert opinion on drug delivery, 12(1), 65-84.
9. Amrutkar, P. P., Patil, S. B., Todarwal, A. N., Wagh, M. A., Kothawade, P. D., & Surawase,
10. R. K. (2010). Design and evaluation of taste masked chewable dispersible tablet of lamotrigine by melt granulation. International Journal of Drug Delivery, 2(2), 183-191.
11. Anil Kumar, Vikas Kaushik, Kuldeep Malodia, Sunil Kumar and Pankaj Rakha (2012): “A Recent Approach on Fast Dissolving Tablets”, Research Journal of Pharmaceutical, Biological and Chemical Sciences, July – September 2012, Vol 3:3, pp. 1209-1219.
12. Arima, H., Higashi, T., & Motoyama, K. (2012). Improvement of the bitter taste of drugs by complexation with cyclodextrins: applications, evaluations and mechanisms. Therapeutic delivery, 3(5), 633-644.
13. Arunachalam, A., Karthikeyan, M., Kumar, S. A., Konam, K., Prasad, P. H., Sethuraman, S., & Manidipa, S. (2010). Fast dissolving drug delivery system: A review. Journal of global trends in pharmaceutical sciences, 1(1), 92-110.
14. Arya, A., Chandra, A., Sharma, V., & Pathak, K. (2010). Fast dissolving oral films: an innovative drug delivery system and dosage form. International Journal of ChemTech Research, 2(1), 576-583.
15. Assaf, S. M., Qandil, A. M., & Al-Ani, E. A. (2013). Fast and pH-dependent release of domperidone from orally disintegrating tablets. Pharmaceutical development and technology, 18(4), 897-905.
16. Bala, R., Pawar, P., Khanna, S., & Arora, S. (2013). Orally dissolving strips: A new approach to oral drug delivery system. International journal of pharmaceutical investigation, 3(2), 67.
17. Bandari, S., Mittapalli, R. K., & Gannu, R. (2014). Orodispersible tablets: An overview. Asian Journal of Pharmaceutics (AJP): Free full text articles from Asian J Pharm, 2(1).
18. Bandari, S., Mittapalli, R. K., & Gannu, R. (2014). Orodispersible tablets: An overview. Asian Journal of Pharmaceutics (AJP): Free full text articles from Asian J Pharm, 2(1).
19. Barghi, L., & Jahangiri, A. (2018). Fast-dissolving nanofibers: As an emerging platform in pediatric and geriatric drug delivery. Journal of advanced chemical and pharmaceutical materials (JACPM), 1(2), 26-28.
20. Barghi, L., & Jahangiri, A. (2018). Fast-dissolving nanofibers: As an emerging platform in pediatric and geriatric drug delivery. Journal of advanced chemical and pharmaceutical materials (JACPM), 1(2), 26-28.
21. Bath PM, Lee HS, Everton LF (2018) Swallowing therapy for dysphagia in acute and subacute stroke. Cochrane Database Syst Rev 10: CD030032.
22. Battu, S. K., Repka, M. A., Majumdar, S., & Rao Y, M. (2007). Formulation and evaluation of rapidly disintegrating fenoverine tablets: effect of super disintegrants. Drug development and industrial pharmacy, 33(11), 1225-1232.
23. Baumann A, Katz PO (2016) Functional disorders of swallowing. Handb Clin Neurol 139: 483-488.
24. Beri, C., & Sacher, I. (2013). Development of fast disintegration tablets as oral drug delivery system-A review. Indian Journal of Pharmaceutical and Biological Research, 1(03), 80-99.
25. Bess W S, Kulkarni N, Ambike SH, Ramsay MP, (2006): “Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1”. US Patent 7067116.
26. Birer, M., & Acartürk, F. (2021). Electrospun orally disintegrating film formulation of telmisartan. Pharmaceutical Development and Technology, 26(6), 661-672.
27. Boateng, J. (2017). Drug delivery innovations to address global health challenges for pediatric and geriatric populations (through improvements in patient compliance). Journal of Pharmaceutical Sciences, 106(11), 3188-3198.
28. Bolhuis GK, Kamp HV and Lerk CF (1986). On the similarity of sodium starch glycolate from different sources. Drug Dev Ind Pharm 12: 621-630.
29. Breitkreutz, J., & Boos, J. (2007). Paediatric and geriatric drug delivery. Expert opinion on drug delivery, 4(1), 37-45.
30. Brooks M, McLaughlin E, Shields N (2019) expiratory muscle strength training improves swallowing and respiratory outcomes in people with dysphagia: A systematic review. Int J Speech Lang Pathol 21: 89-100.
31. Brown, D. (2003). Orally disintegrating tablets-taste over speed. Drug Delivery Technol., 3, 58-61.
32. Chandrasekaran P. and R. Kandasamy, Solid oral flexible formulations for paediatric andgeriatric patients: age-appropriate formulation platforms, Indian J. Pharm. Sci.2018; 80(1):14-25.
33. Chandrasekaran, G., & Rajalakshmi, A. N. (2019). Fixed dose combination products as Oro- dispersible tablets: A review. Journal of Drug Delivery and Therapeutics, 9(2), 563-573.
34. Channer, K. S. & Virgee, J. P., (1986): “The effect of size and shape of tablets on their esophageal transit”. J. Clin. Pharmac. 26: pp. 141-146.
35. Charoo, N. A., Shamsher, A. A., Zidan, A. S., & Rahman, Z. (2012). Quality by design approach for formulation development: a case study of dispersible tablets. International journal of pharmaceutics, 423(2), 167-178.
36. Chein, Y. W. (1992). Novel drug delivery systems. Marcel jekker Inc., New York, 13.
37. Chen, Y. D., Liang, Z. Y., Cen, Y. Y., Zhang, H., Han, M. G., Tian, Y. Q., ... & Yang, D. S. (2015). Development of oral dispersible tablets containing prednisolone nanoparticles for the management of pediatric asthma. Drug design, development and therapy, 9, 5815. `
38. Chowdary, K. R., & Hymavathi, R. (2000). Formulation and dissolution rate studies on dispersible tablets of ibuprofen. Indian journal of pharmaceutical sciences, 62(3), 213.
39. Ciavarella, A. B., Khan, M. A., Gupta, A., & Faustino, P. J. (2016). Dose uniformity of scored and unscored tablets: Application of the FDA Tablet Scoring Guidance for Industry. PDA journal of pharmaceutical science and technology, 70(6), 523-532.
40. Cohen, R., de La Rocque, F., Lécuyer, A., Wollner, C., Bodin, M. J., & Wollner, A. (2009). Study of the acceptability of antibiotic syrups, suspensions, and oral solutions prescribed to pediatric outpatients. European journal of pediatrics, 168(7), 851-857.
41. Cram A., J. Breitkreutz, S. Desset-Brèthes, T. Nunn, C. Tuleu, Challenges of developingpalatable oral paediatric formulations, Int. J. Pharm. 2009; (365):1-3 http://dx.doi.org/10.1016/j.ijpharm.2008.09.015
42. Cuzzolin, L., Atzei, A., & Fanos, V. (2006). Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety. Expert opinion on drug safety, 5(5), 703-718.
43. Deepak K., (2004): “Orally disintegrating tablets”. J. Tablets and Capsules, 2004; 7: pp. 30- 35.
44. Drumond, N., van Riet-Nales, D. A., Karapinar-Çarkit, F., & Stegemann, S. (2017). Patients‟ appropriateness, acceptability, usability and preferences for pharmaceutical preparations: Results from a literature review on clinical evidence. International journal of pharmaceutics, 521(1-2), 294-305.
45. Dutta S and Kumar P. (2011): International Journal Drug Formulation and Research; 2(1): pp. 45-51.
46. EMA (European Medicines Agency). Reflection paper: formulations of choice for the pediatric population (CHMP). Committee for Medicinal Products for Human Use, 3, p 22, 2006.
47. Ernest T., Challenges associated with developing medicines for children-an industryPerspective, EuPFI presentation [Accessed on 12 Dec 2016]
48. ESSD (2012) position Statements: Oropharyngeal dysphagia in adult patients. European Society for Swallowing Disorders.
49. European Medicines Agency 1994, ICH Topic E7, „Note for Guidance for studies in support of Special Populations‟, Geriatrics.
50. European Medicines Agency 2013, „Guideline on the pharmaceutical development of medicines for paediatric use‟.
51. FDA 2001, Guidance for Industry, „Content and Format for Geriatric Labeling‟, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER).
52. FDA 2016. Guidance for Industry, „Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act‟, Food and Drug Administration, Center of Drug Evaluation and Research (CDER), Compounding and Related Documents.
53. Fiocchi A, Riva E, Giovannini M. Ethanol in medicines and other products intended for children. Nutr Res, 1999; 19(3):373–9.
2. AAP (American Academy of Pediatrics), Committee on Drugs. Inactive ingredients in pharmaceutical products: update (subject review). Pediatrics, 1997; 99:268–78.
3. Aastha S, Srinivas N and Sravanthi M., “Formulation and In-Vitro Evaluation of Matrix Type Sustained Release Tablets of Paliperidone”, Innovations in Pharmaceuticals and Pharmacotherapy, 2013, 1 (3), 185-198.
4. Abdul H, Gopinath M, “Formulation and evaluation of Paliperidone Nanocrystals”, Bio Med Rx, 2013, 1 (5), 422-438.
5. Aboelwafa, A. A., & Fahmy, R. H. (2012). A pilot human pharmacokinetic study and influence of formulation factors on orodispersible tablet incorporating meloxicam solid dispersion using factorial design. Pharmaceutical development and technology, 17(1), 1-14.
6. Adolfsson Å˚ , Olsson H, Nyström C. Effect of particle size and compaction load on interparticulate bonding structure for some pharmaceutical materials studied by compaction and strength characterisation in butanol. Eur J Pharm Biopharm. 1997;44(3):243–51.
7. Afaque RMA, Saddamhusen JM, Gosavi JP. Review on artificial sweeteners used in formulation of sugar free syrups. Int J Adv Pharm, 2015; 4(2):2,4.
8. Aleksovski, A., Dreu, R., Gašperlin, M., & Planinšek, O. (2015). Mini-tablets: a contemporary system for oral drug delivery in targeted patient groups. Expert opinion on drug delivery, 12(1), 65-84.
9. Amrutkar, P. P., Patil, S. B., Todarwal, A. N., Wagh, M. A., Kothawade, P. D., & Surawase,
10. R. K. (2010). Design and evaluation of taste masked chewable dispersible tablet of lamotrigine by melt granulation. International Journal of Drug Delivery, 2(2), 183-191.
11. Anil Kumar, Vikas Kaushik, Kuldeep Malodia, Sunil Kumar and Pankaj Rakha (2012): “A Recent Approach on Fast Dissolving Tablets”, Research Journal of Pharmaceutical, Biological and Chemical Sciences, July – September 2012, Vol 3:3, pp. 1209-1219.
12. Arima, H., Higashi, T., & Motoyama, K. (2012). Improvement of the bitter taste of drugs by complexation with cyclodextrins: applications, evaluations and mechanisms. Therapeutic delivery, 3(5), 633-644.
13. Arunachalam, A., Karthikeyan, M., Kumar, S. A., Konam, K., Prasad, P. H., Sethuraman, S., & Manidipa, S. (2010). Fast dissolving drug delivery system: A review. Journal of global trends in pharmaceutical sciences, 1(1), 92-110.
14. Arya, A., Chandra, A., Sharma, V., & Pathak, K. (2010). Fast dissolving oral films: an innovative drug delivery system and dosage form. International Journal of ChemTech Research, 2(1), 576-583.
15. Assaf, S. M., Qandil, A. M., & Al-Ani, E. A. (2013). Fast and pH-dependent release of domperidone from orally disintegrating tablets. Pharmaceutical development and technology, 18(4), 897-905.
16. Bala, R., Pawar, P., Khanna, S., & Arora, S. (2013). Orally dissolving strips: A new approach to oral drug delivery system. International journal of pharmaceutical investigation, 3(2), 67.
17. Bandari, S., Mittapalli, R. K., & Gannu, R. (2014). Orodispersible tablets: An overview. Asian Journal of Pharmaceutics (AJP): Free full text articles from Asian J Pharm, 2(1).
18. Bandari, S., Mittapalli, R. K., & Gannu, R. (2014). Orodispersible tablets: An overview. Asian Journal of Pharmaceutics (AJP): Free full text articles from Asian J Pharm, 2(1).
19. Barghi, L., & Jahangiri, A. (2018). Fast-dissolving nanofibers: As an emerging platform in pediatric and geriatric drug delivery. Journal of advanced chemical and pharmaceutical materials (JACPM), 1(2), 26-28.
20. Barghi, L., & Jahangiri, A. (2018). Fast-dissolving nanofibers: As an emerging platform in pediatric and geriatric drug delivery. Journal of advanced chemical and pharmaceutical materials (JACPM), 1(2), 26-28.
21. Bath PM, Lee HS, Everton LF (2018) Swallowing therapy for dysphagia in acute and subacute stroke. Cochrane Database Syst Rev 10: CD030032.
22. Battu, S. K., Repka, M. A., Majumdar, S., & Rao Y, M. (2007). Formulation and evaluation of rapidly disintegrating fenoverine tablets: effect of super disintegrants. Drug development and industrial pharmacy, 33(11), 1225-1232.
23. Baumann A, Katz PO (2016) Functional disorders of swallowing. Handb Clin Neurol 139: 483-488.
24. Beri, C., & Sacher, I. (2013). Development of fast disintegration tablets as oral drug delivery system-A review. Indian Journal of Pharmaceutical and Biological Research, 1(03), 80-99.
25. Bess W S, Kulkarni N, Ambike SH, Ramsay MP, (2006): “Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1”. US Patent 7067116.
26. Birer, M., & Acartürk, F. (2021). Electrospun orally disintegrating film formulation of telmisartan. Pharmaceutical Development and Technology, 26(6), 661-672.
27. Boateng, J. (2017). Drug delivery innovations to address global health challenges for pediatric and geriatric populations (through improvements in patient compliance). Journal of Pharmaceutical Sciences, 106(11), 3188-3198.
28. Bolhuis GK, Kamp HV and Lerk CF (1986). On the similarity of sodium starch glycolate from different sources. Drug Dev Ind Pharm 12: 621-630.
29. Breitkreutz, J., & Boos, J. (2007). Paediatric and geriatric drug delivery. Expert opinion on drug delivery, 4(1), 37-45.
30. Brooks M, McLaughlin E, Shields N (2019) expiratory muscle strength training improves swallowing and respiratory outcomes in people with dysphagia: A systematic review. Int J Speech Lang Pathol 21: 89-100.
31. Brown, D. (2003). Orally disintegrating tablets-taste over speed. Drug Delivery Technol., 3, 58-61.
32. Chandrasekaran P. and R. Kandasamy, Solid oral flexible formulations for paediatric andgeriatric patients: age-appropriate formulation platforms, Indian J. Pharm. Sci.2018; 80(1):14-25.
33. Chandrasekaran, G., & Rajalakshmi, A. N. (2019). Fixed dose combination products as Oro- dispersible tablets: A review. Journal of Drug Delivery and Therapeutics, 9(2), 563-573.
34. Channer, K. S. & Virgee, J. P., (1986): “The effect of size and shape of tablets on their esophageal transit”. J. Clin. Pharmac. 26: pp. 141-146.
35. Charoo, N. A., Shamsher, A. A., Zidan, A. S., & Rahman, Z. (2012). Quality by design approach for formulation development: a case study of dispersible tablets. International journal of pharmaceutics, 423(2), 167-178.
36. Chein, Y. W. (1992). Novel drug delivery systems. Marcel jekker Inc., New York, 13.
37. Chen, Y. D., Liang, Z. Y., Cen, Y. Y., Zhang, H., Han, M. G., Tian, Y. Q., ... & Yang, D. S. (2015). Development of oral dispersible tablets containing prednisolone nanoparticles for the management of pediatric asthma. Drug design, development and therapy, 9, 5815. `
38. Chowdary, K. R., & Hymavathi, R. (2000). Formulation and dissolution rate studies on dispersible tablets of ibuprofen. Indian journal of pharmaceutical sciences, 62(3), 213.
39. Ciavarella, A. B., Khan, M. A., Gupta, A., & Faustino, P. J. (2016). Dose uniformity of scored and unscored tablets: Application of the FDA Tablet Scoring Guidance for Industry. PDA journal of pharmaceutical science and technology, 70(6), 523-532.
40. Cohen, R., de La Rocque, F., Lécuyer, A., Wollner, C., Bodin, M. J., & Wollner, A. (2009). Study of the acceptability of antibiotic syrups, suspensions, and oral solutions prescribed to pediatric outpatients. European journal of pediatrics, 168(7), 851-857.
41. Cram A., J. Breitkreutz, S. Desset-Brèthes, T. Nunn, C. Tuleu, Challenges of developingpalatable oral paediatric formulations, Int. J. Pharm. 2009; (365):1-3 http://dx.doi.org/10.1016/j.ijpharm.2008.09.015
42. Cuzzolin, L., Atzei, A., & Fanos, V. (2006). Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety. Expert opinion on drug safety, 5(5), 703-718.
43. Deepak K., (2004): “Orally disintegrating tablets”. J. Tablets and Capsules, 2004; 7: pp. 30- 35.
44. Drumond, N., van Riet-Nales, D. A., Karapinar-Çarkit, F., & Stegemann, S. (2017). Patients‟ appropriateness, acceptability, usability and preferences for pharmaceutical preparations: Results from a literature review on clinical evidence. International journal of pharmaceutics, 521(1-2), 294-305.
45. Dutta S and Kumar P. (2011): International Journal Drug Formulation and Research; 2(1): pp. 45-51.
46. EMA (European Medicines Agency). Reflection paper: formulations of choice for the pediatric population (CHMP). Committee for Medicinal Products for Human Use, 3, p 22, 2006.
47. Ernest T., Challenges associated with developing medicines for children-an industryPerspective, EuPFI presentation [Accessed on 12 Dec 2016]
48. ESSD (2012) position Statements: Oropharyngeal dysphagia in adult patients. European Society for Swallowing Disorders.
49. European Medicines Agency 1994, ICH Topic E7, „Note for Guidance for studies in support of Special Populations‟, Geriatrics.
50. European Medicines Agency 2013, „Guideline on the pharmaceutical development of medicines for paediatric use‟.
51. FDA 2001, Guidance for Industry, „Content and Format for Geriatric Labeling‟, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER).
52. FDA 2016. Guidance for Industry, „Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act‟, Food and Drug Administration, Center of Drug Evaluation and Research (CDER), Compounding and Related Documents.
53. Fiocchi A, Riva E, Giovannini M. Ethanol in medicines and other products intended for children. Nutr Res, 1999; 19(3):373–9.
Article Sidebar
Published
Dec 18, 2022
Article Details
How to Cite
Mr. Kiran M. Adchitre, Mr. Nadim S. Khan, Mr. Hemant B. Bansode, & Sachin S. Pingale. (2022). DEVELOPMENT AND EVALUATION OF PATIENT-FRIENDLY DISPERSIBLE TABLETS FOR PEDIATRIC AND GERIATRIC DRUG DELIVERY. Journal of Population Therapeutics and Clinical Pharmacology, 29(04), 5655-5669. https://doi.org/10.69980/5n1j7b63
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Author Biographies
Mr. Kiran M. Adchitre
Lecturer, Adarsh Shikshan Prasarak Mandal's, D. Pharmacy institute, Osmanabad
Mr. Nadim S. Khan
Assistant Professor, ASPMs K. T. Patil College of Pharmacy, Osmanabad.
Mr. Hemant B. Bansode
Assistant Professor, SVERI's College of Pharmacy, Pandharpur.
Sachin S. Pingale
Assistant Professor, Late Laxmibai Phadtare College of Pharmacy, Kalamb Walchandnagar.
How to Cite
Mr. Kiran M. Adchitre, Mr. Nadim S. Khan, Mr. Hemant B. Bansode, & Sachin S. Pingale. (2022). DEVELOPMENT AND EVALUATION OF PATIENT-FRIENDLY DISPERSIBLE TABLETS FOR PEDIATRIC AND GERIATRIC DRUG DELIVERY. Journal of Population Therapeutics and Clinical Pharmacology, 29(04), 5655-5669. https://doi.org/10.69980/5n1j7b63
